Cervera Ricard
Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain.
Thromb Res. 2017 Mar;151 Suppl 1:S43-S47. doi: 10.1016/S0049-3848(17)30066-X.
The antiphospholipid syndrome (APS) is defined by the development of venous and/or arterial thromboses, often multiple, and pregnancy morbidity (mainly, recurrent fetal losses), in the presence of antiphospholipid antibodies (aPL). Some estimates indicate that the incidence of the APS is around 5 new cases per 100,000 persons per year and the prevalence around 40-50 cases per 100,000 persons. The aPL are positive in approximately 13% of patients with stroke, 11% with myocardial infarction, 9.5% of patients with deep vein thrombosis and 6% of patients with pregnancy morbidity. Currently, there is consensus in treating APS patients with thrombosis with long-term oral anticoagulation and to prevent obstetric manifestations with the use of aspirin and heparin. This review summarizes the main knowledge on the clinical and therapeutic aspects of this syndrome.
抗磷脂综合征（APS）的定义是在存在抗磷脂抗体（aPL）的情况下出现静脉和/或动脉血栓形成（常为多发性）以及妊娠并发症（主要是反复流产）。一些估计表明，APS的发病率约为每年每10万人中有5例新发病例，患病率约为每10万人中有40 - 50例。aPL在约13%的中风患者、11%的心肌梗死患者、9.5%的深静脉血栓形成患者和6%的妊娠并发症患者中呈阳性。目前，对于患有血栓形成的APS患者采用长期口服抗凝治疗以及使用阿司匹林和肝素预防产科表现已达成共识。本综述总结了关于该综合征临床和治疗方面的主要知识。
